Is It Still Safe To Buy AstraZeneca plc?

In this strong market, should you still buy AstraZeneca plc (LON: AZN)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I’m always searching for shares that can help ordinary investors like you make money from the stock market. However, many people are currently worried the market has been overheating. 

So right now I’m analysing some of the most popular companies in the FTSE 100, hoping to establish if they can continue to outperform in today’s uncertain economy. 

Today I’m looking at pharmaceutical giant AstraZeneca (LSE: AZN) (NYSE: AZN.US) to determine whether the shares are still safe to buy at 3,139p.

So, how’s business going?

AstraZeneca has fallen out of favour with the market during last year or so, as investors become more anxious about the company’s future. 

In particular, investors are worried about the company’s impending ‘patent cliff’, as AstraZeneca is going to lose the exclusive manufacturing rights to three of its key treatments during the next three years, which combined represent about 45% of the company’s sales.  

Thankfully, with so much of the company’s sales under threat, management has been quick to enact a turnaround plan. 

Indeed, as part of its plan to return to health, AstraZeneca has announced that it is going to cut nearly 10% of its workforce.  In addition, the company has been searching for strategic acquisitions, recently spending around $2 billion on three small biotech companies all with their own treatments in the latter stages of development.

Furthermore, AstraZeneca is hardly running low on ideas itself, with a strong pipeline of 84 new treatments, 13 of which are in the final stages of coming to market.

Expected growth

Unfortunately, while the company works hard to turn itself around, patent expirations and falling sales will continue dent earnings for the next few years. City forecasts currently predict earnings of $5.62 per share for this year (a fall of 12%) and $4.96 for 2014. 

Shareholder returns

AstraZeneca is well known for its strong dividend, and it appears this payout is not going to stop anytime soon. Indeed, the company’s dividend is covered around two-and-a-half times by earnings, giving the company plenty of room to maintain or even increase the payout. 

In addition, AstraZeneca’s dividend yield is currently 5.8% — larger than that of its peers in the pharmaceutical sector, which currently offer an average dividend yield of 4.6%. 

Valuation

Even though AstraZeneca is one of the largest biotechnology companies in the world, due to concerns over its future, the firm trades at a discount to its rivals. 

AstraZeneca currently trades at a historic P/E of 11, while its peers trade at an average historic P/E of around 15. 

Foolish summary

Overall, AstraZeneca is going to have a rough time during the next few years, as the company loses exclusive manufacturing rights to some of its key products. 

That said, the company is working hard to cut costs and has a full pipeline of new treatments in development. So, all in all, I believe that AstraZeneca still looks safe to buy at 3,139p.

More FTSE opportunities

As well as AstraZeneca, I am also positive on the five FTSE shares highlighted within this exclusive wealth report.

Indeed, all five opportunities offer a mix of robust prospects, illustrious histories and dependable dividends, and have just been declared by the Fool as “5 Shares You Can Retire On“!

Just click here for the report — it’s free.

In the meantime, please stay tuned for my next FTSE 100 verdict 

> Rupert does not own any share mentioned in this article.

 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »